Compare Kingsoft Cloud Holdings Limited (KC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kingsoft Cloud Holdings Limited vs Vertex Pharmaceuticals Incorporated — how do they compare? Kingsoft Cloud Holdings Limited trades at $9.26 (market cap $2.71B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 47.1× Kingsoft Cloud Holdings Limited's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Kingsoft Cloud Holdings Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kingsoft Cloud Holdings Limited for 12 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| KC | VRTX | |
|---|---|---|
Market Cap | $2.71B | $127.55B |
Volume | 1,993,765 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $18.21 | $557.96 |
52-Week Low | $8.58 | $407.37 |
Typical Hold Time | 12 Days | 120 Days |
Enterprise Value | $3.03B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kingsoft Cloud (KC) trades at $8.74, down 5.31% today, with a bearish technical outlook despite recent earnings beats. The company shows strong revenue growth with Q2 2026 revenue up 30.8% year-over-year and improving gross margins, though it remains unprofitable with a -5.46% net income margin. Analyst sentiment is positive with 70% buy ratings and a consensus price target suggesting 60.25% upside potential.
The stock presents a growth opportunity driven by AI cloud services expansion and strategic partnerships, particularly with Xiaomi, but faces execution risks amid ongoing losses and competitive pressures in China's cloud market. Investors should weigh the strong growth trajectory against persistent profitability challenges and market volatility.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, amid a bearish technical signal but strong fundamentals. The company reported $12.0B revenue and $4.0B net income for 2025, with robust profitability margins. Recent positive Phase 2b trial results for its kidney disease drug inaxaplin highlight pipeline progress. Support and resistance levels are tightly clustered around the current price, indicating potential for near-term volatility.
Outlook remains positive given dominant cystic fibrosis franchise, high margins, and promising pipeline, though earnings misses and competitive pressures pose risks. Analyst consensus is strongly bullish with a $573.50 price target, suggesting ~14% upside. Key risks include clinical trial outcomes and reliance on core franchise growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kingsoft Cloud Holdings Limited
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
